Citadel Advisors
KALV

Citadel Advisors’s KalVista Pharmaceuticals KALV Stock Holding History

Citadel Advisors’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.44M Buy
71,700
+43,700
+156% +$704K ﹤0.01% 6802
2025
Q4 		$452K Buy
+28,000
New +$371K ﹤0.01% 9274
2025
Q2 		– Sell
-42,400
Closed -$489K – 13854
2025
Q1 		$489K Buy
42,400
+28,900
+214% +$295K ﹤0.01% 8523
2024
Q4 		$114K Buy
13,500
+11,600
+611% +$120K ﹤0.01% 11265
2024
Q3 		$22K Sell
1,900
-7,400
-80% -$93.1K ﹤0.01% 12711
2024
Q2 		$110K Sell
9,300
-6,300
-40% -$73.5K ﹤0.01% 10790
2024
Q1 		$185K Sell
15,600
-34,500
-69% -$460K ﹤0.01% 10438
2023
Q4 		$614K Buy
50,100
+35,600
+246% +$324K ﹤0.01% 7656
2023
Q3 		$140K Buy
14,500
+13,900
+2,317% +$142K ﹤0.01% 10468
2023
Q2 		$5.4K Sell
600
-100
-14% -$922 ﹤0.01% 13505
2023
Q1 		$5.5K Sell
700
-3,900
-85% -$29.1K ﹤0.01% 13865
2022
Q4 		$31.1K Sell
4,600
-202,700
-98% -$1.09M ﹤0.01% 12704
2022
Q3 		$3.01M Sell
207,300
-168,400
-45% -$2.35M ﹤0.01% 4810
2022
Q2 		$3.7M Buy
375,700
+304,200
+425% +$3.36M ﹤0.01% 4373
2022
Q1 		$1.05M Buy
+71,500
New +$1.03M ﹤0.01% 7570
2021
Q3 		– Sell
-24,100
Closed -$577K – 14250
2021
Q2 		$577K Sell
24,100
-18,100
-43% -$474K ﹤0.01% 9732
2021
Q1 		$1.08M Sell
42,200
-24,700
-37% -$649K ﹤0.01% 7919
2020
Q4 		$1.27M Buy
+66,900
New +$1.15M ﹤0.01% 6283

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors's KALV Position: Q1 2026 in Review

Citadel Advisors increased its KalVista Pharmaceuticals (KALV) stake by 159% in Q1 2026, buying an estimated $966K and bringing the position to 97,726 shares worth $1.97M. The position accounts for ﹤0.01% of the portfolio, ranked #6090.

Citadel Advisors first reported a position in KALV in Q2 2015 and has held it in 24 quarters since. The position peaked at $9.6M in Q4 2023. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Citadel Advisors held 97,726 shares of KalVista Pharmaceuticals worth $1.97M as of Q1 2026.
  • Citadel Advisors bought 59,965 KalVista Pharmaceuticals shares in Q1 2026, an estimated $966K.
  • KalVista Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6090 holding.
  • Citadel Advisors first reported a position in KalVista Pharmaceuticals in Q2 2015 and has held it in 24 quarters since.
  • Citadel Advisors's KalVista Pharmaceuticals position peaked at $9.6M in Q4 2023.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.